<DOC>
	<DOCNO>NCT00615693</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , efficacy AEB071 therapy uveitis . Vision improvement reduction swell retina measure assessment efficacy .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy AEB071 Treatment Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<criteria>Male female patient noninfectious intermediate posterior uveitis panuveitis least one eye , age 18 70 year age inclusive , otherwise good health Macular edema average central retinal thickness ≥ 250 µm A vitreous haze score ≥ 1 , ≤ 3 ( base National Eye Institute grade system ) Best Corrected Visual Acuity worse 20/400 good 20/40 Daily prednisone dose &lt; 1 mg/kg Patients choroidal neovascularization . Patients follow form uveitis : 1 . Serpiginous choroidopathy 2 . Acute multifocal placoid pigment epitheliopathy 3 . White dot retinochoroidopathies ( e.g. , multiple evanescent white dot syndrome ( MEWDS ) multifocal choroiditis ) Macular edema associate ocular disease ( e.g. , diabetic retinopathy ) Patients prior vitrectomy Any eye condition may affect evaluation visual acuity retinal thickness Concurrent use certain immunosuppressive agent ( specific washout period different agent define protocol ) Use systemic medication know toxic lens , retina , optic nerve ( e.g . deferoxamine , chloroquine , ethambutol ) currently past 6 month Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Macular Edema</keyword>
</DOC>